Box 1: Recent Trump Administration Obesity Drug Initiatives In November 2025, the Trump administration announced reaching a deal with Eli Lilly and Novo Nordisk to lower the cost of their GLP-1s for Medicare, Medicaid, and those purchasing the drugs directly from the manufacturers through a new TrumpRx website
Retatrutide is a next-generation triple receptor agonist that simultaneously activates GLP-1, GIP, and glucagon receptors, making it one of the most studied compounds in modern metabolic peptide research
The science of transdermal patches: what works and what doesn't Why "GLP-1 patches" is misleading Inside the patch: an ingredient-by-ingredient look What real customers actually say Cost: are Kind Patches good value
A simple log, even just three lines per day noting energy, appetite, and any side effects, reveals patterns within two to three weeks that you would never notice otherwise